I have worked for a long time in the cell line development team of a company called Aprogen. I was quite surprised when I saw the content related to the simulator in the Asimov email because it was something I had been thinking about and wanted to try.
During my long involvement in cell line development, I always had doubts about the traditional labor-intensive process used in cell line development. During this time, as a long-time fan of F1 racing, I wondered if the simulator used by the F1 racing team for vehicle development could be applied to cell line development. I wanted to use the data from the simulator to accumulate data for cell line development processes without conducting actual tests, thereby reducing labor input, and making the process more efficient.
Based on the data obtained from the simulator, I have three different concepts for developing CHO cell lines, primarily focusing on highly productive and stable cell lines, highly productive and less stable cell lines, and having a great quality but not stable cell lines. For processes that require a large quantity of drugs such as antibodies or recombinant proteins using perfusion cultivation, I would supply a highly productive and stable cell line. A highly productive and less stable cell line is suitable for during the fed-batch production period. For drugs where quality is more important than high production volume, such as orphan drugs, I believe it's possible to develop cell lines based on different concepts, even if they are unstable but able to produce great quality of protein, and highly productive. Over time, with the accumulation of data, we can model DNA sequences, amino acid sequences, and transfection site optimization with a stable and reliable simulator. If adjustments can be made at the DNA sequence level, we can use the CRISPR system for editing, aligning with the host cell engineering of CHO cells for stable growth, high productivity, and stability, tailored to the characteristics of the required drug. I believe that having various concepts and a highly reliable simulator will enable more accurate predictions of the production process. This could lead to cost reduction and profit increase for pharmaceutical companies or CDMO firms, as they could optimize the size of bioreactors used in GMP factories and potentially reduce costs in the downstream process, though it's important to note that the cost of column usage in the purification process may not be reduced if the cell line produces a large quantity.
To implement these ideas, I believe that using a simulator based on developing computer technology is an effective way to save time and reduce labor in initial cell line development. Therefore, I decided to study bioinformatics for a master's degree program in the UK and the Netherlands for 2024/2025. I decided to study in the UK because approximately 70% of the entire F1 racing teams are based. I hope to learn from the practical simulator personnel in the F1 racing teams located in the UK.
Receiving the CHO simulator email has given me a goal to work in a place that aligns with my thoughts. I believe that working for a company where I can address these ideas is a great opportunity for personal growth. After completing my bioinformatics master's program, I want to work at Asimov, but I'm curious about whether there is a way for a foreigner (a Korean) to apply for a position.
Hello, my name is Sanghee Lee.
I have worked for a long time in the cell line development team of a company called Aprogen. I was quite surprised when I saw the content related to the simulator in the Asimov email because it was something I had been thinking about and wanted to try.
During my long involvement in cell line development, I always had doubts about the traditional labor-intensive process used in cell line development. During this time, as a long-time fan of F1 racing, I wondered if the simulator used by the F1 racing team for vehicle development could be applied to cell line development. I wanted to use the data from the simulator to accumulate data for cell line development processes without conducting actual tests, thereby reducing labor input, and making the process more efficient.
Based on the data obtained from the simulator, I have three different concepts for developing CHO cell lines, primarily focusing on highly productive and stable cell lines, highly productive and less stable cell lines, and having a great quality but not stable cell lines. For processes that require a large quantity of drugs such as antibodies or recombinant proteins using perfusion cultivation, I would supply a highly productive and stable cell line. A highly productive and less stable cell line is suitable for during the fed-batch production period. For drugs where quality is more important than high production volume, such as orphan drugs, I believe it's possible to develop cell lines based on different concepts, even if they are unstable but able to produce great quality of protein, and highly productive. Over time, with the accumulation of data, we can model DNA sequences, amino acid sequences, and transfection site optimization with a stable and reliable simulator. If adjustments can be made at the DNA sequence level, we can use the CRISPR system for editing, aligning with the host cell engineering of CHO cells for stable growth, high productivity, and stability, tailored to the characteristics of the required drug. I believe that having various concepts and a highly reliable simulator will enable more accurate predictions of the production process. This could lead to cost reduction and profit increase for pharmaceutical companies or CDMO firms, as they could optimize the size of bioreactors used in GMP factories and potentially reduce costs in the downstream process, though it's important to note that the cost of column usage in the purification process may not be reduced if the cell line produces a large quantity.
To implement these ideas, I believe that using a simulator based on developing computer technology is an effective way to save time and reduce labor in initial cell line development. Therefore, I decided to study bioinformatics for a master's degree program in the UK and the Netherlands for 2024/2025. I decided to study in the UK because approximately 70% of the entire F1 racing teams are based. I hope to learn from the practical simulator personnel in the F1 racing teams located in the UK.
Receiving the CHO simulator email has given me a goal to work in a place that aligns with my thoughts. I believe that working for a company where I can address these ideas is a great opportunity for personal growth. After completing my bioinformatics master's program, I want to work at Asimov, but I'm curious about whether there is a way for a foreigner (a Korean) to apply for a position.